Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response.
|Title||Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response.|
|Publication Type||Journal Article|
|Year of Publication||2006|
|Authors||Wong, M-L, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM, McCann SM, Licinio J|
|Journal||Proceedings of the National Academy of Sciences of the United States of America|
|Date Published||2006 Oct 10|
|Keywords||Adult, Aged, Antidepressive Agents, Cyclic Nucleotide Phosphodiesterases, Type 1, Depressive Disorder, Major, Desipramine, Double-Blind Method, Female, Fluoxetine, Genetic Predisposition to Disease, Humans, Male, Mexican Americans, Middle Aged, Phosphoric Diester Hydrolases, Polymorphism, Single Nucleotide, Prospective Studies, Single-Blind Method|
Cyclic nucleotide phosphodiesterases (PDEs) constitute a family of enzymes that degrade cAMP and cGMP. Intracellular cyclic nucleotide levels increase in response to extracellular stimulation by hormones, neurotransmitters, or growth factors and are down-regulated through hydrolysis catalyzed by PDEs, which are therefore candidate therapeutic targets. cAMP is a second messenger implicated in learning, memory, and mood, and cGMP modulates nervous system processes that are controlled by the nitric oxide (NO)/cGMP pathway. To investigate an association between genes encoding PDEs and susceptibility to major depressive disorder (MDD), we genotyped SNPs in 21 genes of this superfamily in 284 depressed Mexican Americans who participated in a prospective, double-blind, pharmacogenetic study of antidepressant response, and 331 matched controls. Polymorphisms in PDE9A and PDE11A were found to be associated with the diagnosis of MDD. Our data are also suggestive of the association between SNPs in other PDE genes and MDD. Remission on antidepressants was significantly associated with polymorphisms in PDE1A and PDE11A. Thus, we found significant associations with both the diagnosis of MDD and remission in response to antidepressants with SNPs in the PDE11A gene. We show here that PDE11A haplotype GAACC is significantly associated with MDD. We conclude that PDE11A has a role in the pathophysiology of MDD. This study identifies a potential CNS role for the PDE11 family. The hypothesis that drugs affecting PDE function, particularly cGMP-related PDEs, represent a treatment strategy for major depression should therefore be tested.
|Alternate Journal||Proc. Natl. Acad. Sci. U.S.A.|